New bone formation and cancer implants; relationship to tumour proliferative activity. by Nemoto, R.
Br. J. Cancer (1991), 63, 348 350 1991
New bone formation and cancer implants; relationship to tumour
proliferative activity
R. Nemoto
The Department of Urology, Tottori University School ofMedicine, Yonago 683, Japan.
Summary The interaction between tumour and bone with respect to the proliferative activity of transplanted
tumour cells was studied using five transplantable human urogenital tumours in nude mice. Cells from those
tumours were injected subcutaneously over the calvaria of nude mice following disruption of the periosteum.
The extent of tumour-bone interaction varied with the type of implanted tumour as shown on X-ray and by
histologic examinations of the calvaria. The classic histologic pattern of bone remodelling including the
destruction of bone with proliferation of osteoclasts and reactive new bone formation was seen with all five
tumours. Tumour proliferative activity determined from the tumour doubling time and the S-phase fraction
using bromodeoxyuridine labelling showed that the rate of reactive bone formation appeared to be inversely
proportional to the rate of tumour cell proliferation.
We previously described a model for studying the interac-
tions of tumour and bone in mice and had suggested the
possibility of the development of skeletal metastases concur-
rent with the formation and destruction of bone (Nemoto et
al., 1987; Nemoto et al., 1988; Nemoto et al., 1990b). In this
investigation we describe the reaction of bone to transplanted
tumours considering tumour doubling time and the S-phase




Specimens of malignant primary tumours were obtained at
surgery. Fragments of tumour were aseptically implanted
subcutaneously in the right flank of nude mice (Balb/c-nu/nu).
The mice were maintained under pathogen-limited condi-
tions. Five different urogenital tumours including two renal
cell carcinomas (RCC4, RCC5), one transitional cell car-
cinoma of the renal pelvis (RPC1), one transitional cell car-
cinoma of the bladder (TCCI) and one prostate carcinoma
(TSU-PRI) have been serially transplanted at intervals of 2
to 6 months without failure. All tumours preserved the histo-
logic characteristics of the original tumours in nude mice.
Considering the five tumours studied, RCC4 was a renal
cell carcinoma from a patient with multiple osteolytic bone
metastases and lung metastases. RCC5 was an invasive renal
cell carcinoma from a patient who died of multiple osteolytic
bone metastases and liver metastases. RPC1 was a poorly
differentiated transitional cell carcinoma of the renal pelvis
from a patient without distant metastases. TSU-PRI was a
poorly differentiated carcinoma of the prostate from a
patient with multiple bone metastases. His X-rays revealed
osteoblastic bone metastases. TCC1 was a poorly
differentiated transitional cell carcinoma of the bladder from
a patient who died of multiple pulmonary metastases.
Estimation of tumour doubling time
The transplanted tumour was measured externally in the
flank with a caliper once a week and its weight (mg) was
calculated from the formula: tumour weight (mg) = W2 x L/2,
where W is the width of the tumour in mm and L is the
length in mm. Rapid growth of each transplanted tumour
was observed, particularly during the exponential growth
phase. The doubling time (Td) of tumour weight during this
phase as calculated from three different growth curves was
defined as: K = (InVt-InV0)/t, D = In2/Td where t is the time
between measurement, VO is the volume at first measurement
and Vt is the volume at last measurement.
Induction ofosteolysis
When the resulting tumour was visible, it was aseptically
excised and minced in Medium 199. The minced tumour was
further disrupted by repeated syringing. The cell suspension
containing more than 106 viable cells in 0.2 ml medium was
subcutaneously inoculated over the calvaria of nude mice.
The viability of tumour cells was assessed by using the trypan
blue dye exclusion test. As the tumour cells were inoculated,
the needle was used to scratch the bone surface, which
disrupted the periosteum. As control, 0.2 ml of Medium 199
without tumour cells was subcutaneously injected over the
calvaria after scratching the periosteum. Five to seven nude
mice were used in each experiment.
The mice were killed when the tumour grew enough to
cover the calvaria, as large as 15 to 20 mm in diameter, at
day 30 to day 60 after the tumour cell implantation. Control
animals were sacrificed at day 40. Two diameters were
measured with a caliper at right angles to each other. The
parietal bones attached tumour transplants were fixed in 10%
formalin, and were radiographed with a Softex CSM using
Kodak fine film for softex. X-rays were examined under blind
conditions. The area of bone resorption from X-ray detect-
able lesions was measured by computerised analysis using
Graphtec software for plotters.
Histomorphometric evaluation ofbone reaction (Parfitt, 1988)
After the decalcification by EDTA, the specimen was pro-
cessed for histologic examination. Three sections were cut
from each block and stained with hematoxylin-eosin. The
area of new bone formation was measured by the point
counting method with an objective micrometer in each area
reduced by 40 x. The fields to be counted were chosen from
a representative area of new bone formation. Enumeration
was performed by one observer on triplicate sections from
one paraffin block for each of five to seven mice calvarias for
each tumour. The relative new bone-forming surface (osteoid
surface) was expressed as the ratio of reactive new bone
formation area over the total bone area.
Estimation ofSphasefraction (Gratzner, 1982; Nemoto et
al., 1990a)
All mice were given a intraperitoneal infusion of bromo-
deoxyuridine (RADIBUD, Takeda Drug Co. Ltd., Osaka,
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Japan), 25 mg kg-', 2 h before sacrifice. The excised speci-
mens were fixed with 70% ethanol, embedded in paraffin,
sectioned, and stained by an indirect immunoperoxidase
method using anti-BrdU monoclonal antibody (Fujisawa
Co., Osaka, Japan) as the first antibody. Tissue sections were
denatured for 1 h in 2N HCI covered with a 1:10 dilution of
purified anti-BrdU monoclonal antibody in phosphate-
buffered saline containing 0.5%. Tween 20 and left at room
temperature for 45 min. The slides were reacted with a 1:200
dilution of peroxidase-conjugated anti-mouse immuno-
globulin (Ig) G antibody in phosphate-buffered saline for
45 min at room temperature and then with 0.025% diamino-
benzidine tetrahydrochloride and 0.003% in Tris-
hydrochloride buffer for 10 to 15 min. Finally, the slides were
lightly counterstained with 10% Gill hematoxylin. The
remaining portion of each excised tumour specimen was fixed
in 10% formalin for routine histologic examination.
About 1000 cells were counted in each of three to five
microscopic fields to determine the average S-phase fraction.
The field to be counted was selected under 40 x
magnification from the well labelled area, and an ocular grid
at 400 x magnification was used. Malignant cells were
counted consecutively in the 100-grid squares, moving from
right to left and then down as in reading a page. The S-phase
fraction was expressed as the ratio of BrdU-labelled cells to
the total number of cells counted.
Reactive bone formation, tumour doubling time and S-
phase fraction and area of bone resorption were statistically
evaluated with the Pearson correlation coefficient. Results are
presented as mean ± standard deviation.
Results
Bone lesions of varying degrees were detected in the micro-
scopic examination as well as in the X-rays. RPC-1 and
TSU-PRI showed marked osteolytic lesions as compared
with RCC4 and RCC5 (Table I). No tumour showed osteo-
blastic changes on X-rays.
A multinucleated giant cell, an osteoclast, in a small
lacunae between invading tumour and bone were evident in
each tumour. There were a few osteoclasts in the deep
invasive lacunae in the bone cortex. While a slight extent of
reactive periosteal new bone formation was observed
associated with osteoclastic bone destruction in tumours
TSU-PR1 and RCC4 (Figure la,b), marked extent of
reactive bone formation was observed in tumours RCC5 and
RPCI (Figure lc,d). The properties whereby the tumour
interacted with bone varied according to tumour as shown in
Figure 1. Control mice showed no microscopic changes in the
calvaria.
Table I shows the relationship between tumour and bone
and the proliferative activity of the tumour in the individual
tumours according to tumour doubling time and S-phase
fraction. There was no correlation between the extent of
reactive bone formation and the osteolytic activity evaluated
by the area of bone resorption on X-ray (r = 0.001, P = 0.9).
However, the doubling time of the two fast-growing tumours
(TSU-PR1; 5.8 ± 1.5, RCC4; 8.6 ± 2.1) showed a slight
amount of reactive bone formation (14.1 + 10.4, 19.8 9.1),
whereas the three slow-growing tumours (RCC5; 12.3 + 1.4,
RPCI; 12.9 ± 2.6, TCCI; 18.6 + 2.0) showed a marked
amount of reactive bone formation (47.0 ± 8.6, 52.3 ± 7.2,
55.6 ± 9.9). This shows a strong correlation between the
reactive bone formation and the tumour doubling time
(r = 0.91, P = 0.03). Those tumours with higher S phase
fractions (TSU-PR1; 29.8 ± 5.4, RCC4; 31.1 ± 3.9) showed
less reactive bone formation compared with those having a
lower S-phase fraction (RCC5; 23.6 ± 0.7, TCC1; 16.0 ± 1.0).
An inverse correlation between reactive bone formation and
S-phase fraction (r = 0.94, P = 0.06).
Discussion
Although postmortem X-rays of the nude mice calvaria
showed a markedly destructive osteolytic lesions in all mice
with implanted tumours, no osteoblastic changes was
observed. However, all tumours microscopically showed the
resorption cavities with multinucleated giant cells adjacent to
a tumour and reactive periosteal new bone formation. The
present study also suggests that skeletal metastases are
associated with both the reactive formation of new bone and
bone destruction. Milch and Changus examined microscopic
sections of bone metastases in 241 patients with different
types of cancer (Milch & Changus, 1956). They found a
predominantly sclerotic type of lesion in 30% of lung
cancers, in 60% of breast cancers, and in 90% of prostatic
cancers. The process was histologically identical in all types
of tumour. A similar conclusion was reached by Fornasier
and Horne who examined 140 autopsies with vertebral
metastases and attempted to distinguish lytic from sclerotic
lesions in the microscopic sections (Fornasier & Horne,
1975). They found that the majority of bone metastases
showed a combination of both features. Galasko examined
new bone formation in vertebral metastases in 69 patients
(Galasko, 1975). He concluded, as did the previous investi-
gators, that there is no basic difference between lytic and
sclerotic metastases-microscopically, practically all meta-
stases are mixed, and the radiological appearance merely
reflects the predominant process.
Milch and Changus postulated that reactive new bone
represented a response to stress on the weakened bone
similar to callus formation in fracture healing (Milch &
Changus, 1956). Since reactive bone formation occurred in
response to bone destruction, they regarded this as an
attempt to repair the bone injury caused by the cancer. A
predominance of tumour growth activity led to an osteolytic
lesion while a predominance of repair processes led to an
osteoblastic lesion. Galasko reported that new bone form-
ation occurs in virtually all bone metastases except those
associated with large and highly anaplastic tumours in micro-
scopic study (Galasko, 1975). He also found new bone for-
mation to have a woven character similar to that seen with
callus formation.
We observed similar findings in our study. That is, fast-
growing transplantable human tumours in nude mice, as
estimated from the tumour doubling time and the S-phase
fraction, showed less reactive bone formation than did the
slow-growing tumours. The extent of reactive bone formation
appeared to be inversely proportional to the rate of tumour
growth. The formation of reactive new bone seemed to be a
tissue reaction against tumour-induced osteolysis and could
represent an attempt to repair the injury produced by tumour
cells. The formation of new bone might increase if the
Table I Tumour bone interaction induced by human urogenital tumours in nude mice
Tumour Area of bone Reactive bone Doubling S-phase
Tumour (n) size (mm) resorption (mm2)a formation (%) time (day) fraction (%)
TSU-PC1 (5) 20.1 1.8b 8.5 ± 4.7 14.1 ± 10.4c 5.8 ± 1.5 29.8 ± 5.4
RCC4 (7) 19.5 3.2 1.1 0.4 19.8 9.1 8.6 2.1 31.1 ± 3.9
RCC5 (7) 20.0 2.4 5.7 2.9 47.0 8.9 12.3 ± 1.4 23.6 ± 0.7
RPC1 (7) 18.9 ± 3.7 14.1 ± 6.6 52.3 ± 7.2 12.9 ± 2.6
TCC1 (7) 14.6±2.1 6.9±3.1 55.6± 9.9 18.6±2.0 16.8 1.0
aEvaluated on X-ray. bMean values ± standard deviation. cThe relative new bone-forming surface is
expressed as the ratio of the area of reactive bone formation to the total area of bone.350 R. NEMOTO
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Figure 1 Sectiorts of mouse calvaria with transplantable human tumours implanted subcutaneously over the calvaria. a, TSU-PR1
tumour;. a large lacunae betwen invading tumour and reactive new bone formation was observed (x 125), b, RCC4 tumour; slight
reactive bone formation was observed associated with osteoclastic bone destruction (x 125), c, RCC5 tumour (x 125), d, RPCI
tumour (D, x 40). Marked reactive bone formation was observed in c and d.
tumour grew only slowly at the metastatic site. Slow-growing
tumours may lead to a gradual thickening of the cortex
which then appears on the X-rays as osteoblastic metastasis.
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